The radiotherapy treatment comes from an electrical machine called a ‘Linear accelerator’ and is directed as a beam to the part of the body that needs to be treated. Treatment is given daily over a period of days or weeks and you may hear people call these treatments ‘fractions’. They are just a fraction of your treatment dose and plan.
Immunotherapy is a biological therapy and type of targeted treatment that boosts the patient’s natural defence, the immune system, and enables it to find and destroy cancer cells found in the body. At Rutherford Cancer Centres, we use several different types of immunotherapy in the treatment of cancer, in order to prevent cells growing and replicating or spreading around the body.
Chemotherapy at the Rutherford takes place in our modern therapy suites, consisting of up to ten treatment areas offering treatment for haematology/oncology patients requiring systemic anti-cancer therapy (SACT) and supportive care in an outpatient setting. The infusion therapy suites are available for patients undergoing treatment for breast, urology, upper and lower gastrointestinal cancers, and both malignant and non-malignant haematology disorders.
Dr Jason Lester is a senior Consultant Clinical Oncologist based in South Wales. He trained and qualified in United Medical and Dental Schools of Guy’s & St Thomas’s in 1993. He completed his general medical training in London and the South East of England before moving to Wales in 1997. He joined Velindre Cancer Centre in 1997 and completed his Clinical Oncology training in 2003.
Dr Lester was appointed as a consultant Oncologist in 2003, specialising in the management of lung (non-small cell, small cell, mesothelioma) and urological (prostate, kidney, bladder) cancers. His NHS practice is based in South East Wales, with clinics in The Royal Gwent Hospital Newport, University Hospital Llandough, Cardiff and Velindre Cancer Centre, Cardiff. He is an Associate Clinical Director at Velindre and Director of Stepping Stones, the Wales-based lung cancer charity.
He is currently Deputy Clinical Director of Velindre Cancer Centre, and Chairman of the Rutherford Cancer Centre Local Medical Advisory Committee for Wales. He is also the Clinical Lead for the All Wales Prostate Cancer Brachytherapy Service.
Dr Lester participates in a large number of clinical trials in both lung and urological cancer sites, and has published extensively in these fields. He is the lead investigator in the I-START trial, (dose escalated radiotherapy) and the SKOPOS trial, a vaccine trial in malignant pleural mesothelioma. He is responsible for prescribing and supervising the administration of radiotherapy, radioisotope treatment, cytotoxic chemotherapy and hormone therapy.
Find out more by visiting Dr Jason Lesters website: www.lester-oncology.org
* Within the website, links to external sites and resources may be provided by third parties. Links to such sites are provided purely for your information only. It is the responsibility of the third party organisation to ensure any content on their websites comply with all relevant laws and regulations. Such links should not be interpreted as approval by us of those linked websites or information you may obtain from them. We have no control over the contents of those sites or resources. Our full Website terms of use can be found here.
Dr Jason Lester does not hold a share or financial interest in the Rutherford Cancer Centres or another Proton Partners International company.
Dr Jason Lester does not have a share or financial interest in equipment used at the Rutherford Cancer Centres or another Proton Partners International company.
Dr Jason Lester does hold a paid advisory role(s) at the Rutherford Cancer Centres or on behalf of Rutherford Cancer Centres or Proton Partners International.
If you'd like to speak to us about any of the treatments we offer please don’t hesitate to get in touch. Call us on 0800 210 0402 or